FreeTalk @ Nomadlife

Pramipexole (2-amino-4,5,6,7-tetrahydro-6-propyl-amino-benzthiazole-dihydrochl
oride), a new dopamine receptor agonist with preference for D3
compared to D2 and D4 receptors, was tested in rats in respect of its
potential antidepressant activity. In the forced swimming test the
drug under study, given three times in rats, reduced the immobility
time. In the forced swimming test, joint treatment with
antidepressants (imipramine, amitriptyline) and pramipexole evoked a
more potent effect than any of the drugs given alone; however, the
locomotor hyperactivity was weaker after joint administration.
Citalopram and fluoxetine, inactive per se in the forced swimming
tests, visibly enhanced the antidepressant-like effect of pramipexole
but, on the other hand, they attenuated the locomotor hyperactivity
evoked by the drug. Repeated treatment with pramipexole (0.3 or 1
mg/kg, twice daily for 14 days) increased the locomotor activity
measured at 1 h after the last dose. Repeated administration of
pramipexole (as above) potentiated the D-amphetamine- or
quinpirole-induced locomotor hyperactivity. The obtained results
indicate that, in the tests used, pramipexole evokes effects similar
to those of typical antidepressants and, at the same time, enhances
their activity (the forced swimming test in rats); therefore it may be
regarded as a potential antidepressant drug.